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Sllmmsry 
Experimental autoimmune encephalomyelitis (EAE)  is an inflammatory disease of the central 
nervous system that can be induced in a number of species by immunization with myelin basic 
protein (MBP) in adjuvant, and serves as an experimental model for the study of multiple sclerosis. 
The role of the thymus in acquired tolerance in autoimmune models has not been thoroughly 
investigated. In this study, we examined the effects of intrathymic injection of MBP or its major 
encephalitogenic peptide on the course of EAE in Lewis rats. A single intrathymic injection of 
MBP 48 h pre- but not postimmunization protects animals from actively induced EAE. An intact 
MBP-primed thymus was required up to 10 d postimmunization, as thymectomy on days 1, 
2, and 7 postimmunization abrogated the protective effect, whereas thymectomy on day 10 did 
not. The proliferative response of primed lymphocytes was significantly reduced in animals that 
were intrathymically injected with MBP. Protection against clinical EAE was induced by thymic 
injection of the major encephalitogenic region (residues 71-90) but not a nonencephalitogenic 
(21-40) MBP epitope. Immunohistologic  examination of the brain from rats intrathymically injected 
with encephalitogenic peptide showed markedly reduced cellular infiltrate and virtual absence 
of activation and inflammatory cytokines as compared with rats intrathymicaUy injected with 
the nonencephalitogenic peptide. These results indicate that the thymus may play an active role 
in acquired systemic immunologic  tolerance in T cell-mediated experimental autoimmune diseases. 
This effect may be mediated by a process of clonal inactivation of autoreactive T cell clones circulating 
through the thymus. 
E 
xperimental autoimmune encephalomyelitis (EAE) 1 is an 
inflammatory disease of the central nervous system that 
can be induced in a number of species by injection of myelin 
basic protein (MBP) with adjuvant (1). In the Lewis rat, the 
major encephalitogenic determinant is peptide 71-90 of guinea 
pig  MBP  (2,  3).  Nonencephalitogenic epitopes of MBP, 
residues 21-40 for example, are immunogenic and can generate 
a cell-mediated immune response without inducing disease 
(4,  5). 
The thymus plays the major role in development of self- 
tolerance. Tolerance to autoantigens is mediated by clonal de- 
letion or clonal anergy (6, 7), and recent evidence suggests 
that different types of APC in the thymus mediate different 
responses (8, 9). However, it is unclear how tolerance to self- 
1 Abbreviations  used  in  this  paper: EAE,  experimental  autoimmune 
encephalomyelitis;  MBP,  myelin basic protein; p, peptide. 
antigens not constitutively expressed in the thymus is medi- 
ated, and the role of the thymus in acquired systemic toler- 
ance has not been thoroughly investigated. There is evidence 
that a subset of peripheral T cells, when activated, circulate 
to the thymus (10), providing a potential mechanism for pe- 
ripheral activated cells to be exposed to thymic APC and be- 
come inactivated. 
More than 20 yr ago Ellison and Waksman (11) induced 
partial tolerance to EAE by injecting MBP into the shielded 
thymus but not into the shielded spleen of irradiated Lewis 
rats.  Recently there has been renewed interest in studying 
the role of the thymus in acquired systemic tolerance. Thymic 
injection of pancreatic islet cells prevents autoimmune dia- 
betes in the BB rat (12, 13) and the NOD mouse (14). In 
addition, intrathymic injection of donor cells (15, 16), or syn- 
thetic dass II MHC allopeptides (17), induce specific  unrespon- 
siveness to skin (15) and vascularized allografts (16, 17). There 
are no data on the systemic effects of thymic recognition of 
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experimental autoimmune model such as EAE. 
Using intrathymic injection of guinea pig MBP or syn- 
thetic MBP peptides in adult Lewis rats that were not irradi- 
ated or subjected to other immunological manipulations, we 
found that we can induce systemic unresponsiveness  and sup- 
press clinical and pathological features of EAE. Intrathymic 
injection of MBP or MBP peptides provides a novel approach 
for studying antigenic epitopes and investigating the role of 
the thymus in acquired systemic tolerance. 
Materials and Methods 
Induction of EAE.  Female  Lewis rats 6-8 wk of age were ob- 
tained from Charles River Inc. (Wilmington, MA). EAE was in- 
duced by immunizing the animals in the foot pad with 50 #g of 
MBP in CFA. Scoring of clinical disease was performed as previ- 
ously described (18). Duration of disease  was calculated  by counting 
the total number of days from clinical onset to recovery for each 
animal; mean duration was calculated as the average for the whole 
group. Maximal grade is the highest clinical  grade achieved  for each 
animal; mean maximal grade is calculated as the average for each 
group. Statistical analysis was performed using a one-tailed stu- 
dent's t test. Disease index is a composite score and was calculated 
as follows: mean duration of disease x mean highest disease grade 
x  incidence (18). 
Antigens.  Preparation  of guinea pig MBP was performed as pre- 
viously described (18). Peptide sequences were obtained from pub- 
llshed data (19), and MBP peptides were prepared at the Biopolymer 
Center at the Center for Neurologic Diseases of the Brigham and 
Women's Hospital (Boston, MA). 
Intrathymic Injections.  Intrathymic injections were performed 
under ether anesthesia by exposing the thymus through a small 
incision above the sternum. Volumes up to 50/~1 can be injected 
into each lobe, without evidence  of  leakage, using a 27-gauge  needle. 
Thymic injections were performed 48 h before immunization un- 
less specified otherwise. Experimental animals were injected with 
MBP or MBP peptides. Control animals were injected with PBS 
or OVA. 
Thymectomy.  Under ether anesthesia, the sternum was opened 
as for thymic injection and the thymus was removed using forceps. 
The chest wall was sutured after ensuring that no bleeding  occurred. 
Proliferation Assays.  Draining lymph nodes were collected  from 
Lewis rats immunized with MBP/CFA on day 10 postimmuniza- 
tion. The lymph nodes were passed through 60-gauge sterile stain- 
less steel sieves to make single-cell  suspensions.  The cells  were washed 
in HBSS (Sigma Chemical Co., St. Louis, MO) then resuspended 
in RPMI 1640 (Whitaker Bioproducts, Walkersville, MD) con- 
taining 10% (vol/vol) FCS, penicillin (100 U/ml), streptomycin 
(100/~g/ml), 20/~M 2-ME, and 5 mM Hepes. The cells were plated 
in flat-bottomed 96-well plates at a concentration of 106/ml. An- 
tigen was added at 10-50/~g/ml. The plates were incubated  at 37~ 
with  5%  CO2  for  4  d,  then  pulsed with  [3H]thymidine (1 
/zCi/well), harvested, and placed in a beta counter. Experiments 
were  performed in  quadruplicate and  results expressed as  ex- 
perimental counts per minute. Relative response is calculated as: 
Acpm of experimental group/Acpm  of control group. 
Antibodies.  Murine  mAbs  were obtained,  unless otherwise 
specified, from Sera-Lab (Accurate  Chem. & Sci. Corp., Westbury, 
NY). This panel included mAbs to all rat leukocytes  (CD45, OX- 
1); all T cells (CD5, OX-19); TCR c~/B  chains (R73); T cell subsets 
(CD4, BWH-4; CD8, OX-8); and mononuclear  phagocytes  (ED-1, 
ED-2). Activation of mononuclear or endothelial cells  was assessed 
using antibodies to class II antigens (OX-3); p-55 chain of the IL- 
2R (CD25, ART-18; courtesy of  Dr. T. Diamantstein, Berlin, Ger- 
many); intercellular adhesion molecule I (ICAM-1; CD54, 1A29); 
and by labeling for the cytokines IblB (Olympus Corp. Precision 
Instr. Div. Lake Success, NY); I1,-2 (15); IL-4 (Genzyme, Boston, 
MA); IL-6  (R&D, Minneapolis,  MN); Ib8 (ICN, Costa Mesa, CA); 
IFN-3, (courtesy of Dr. P. van der Meide, Rijswijk,  Holland); 
TNF-cx (courtesy  of  Dr. I. McKenzie,  Melbourne, Australia); TGF-3 
(R&D); and PGE2 (Sigma Chemical Co.). Rat Ig-absorbed goat 
anti-mouse Ig (Sigma  Chemical  Co.), rabbit anti-goat Ig and rabbit 
peroxidase-antiperoxidase (Dako Corp., Santa Barbara, CA) were 
obtained  commercially.  Details of  the use of these antibodies,  isotype- 
matched control mAb, and purified rabbit Ig in immunohistologic 
studies were recently described (20, 21). 
Immunohistology.  Brain  samples (cerebrum and cerebellum) were 
harvested from each rat at day 12 after disease induction (three 
samples/group). Tissues were frozen in liquid nitrogen and stored 
at  -80~  in preparation for immunohistologic studies, or fixed 
in neutral-buffered formalin, embedded in paraffin, and sectioned 
for light microscopy. Cryostat sections were fixed in paraformal- 
dehyde-lysine-periodate  for demonstration of leukocytes and acti- 
vation antigens, or in acetone for the labeling of cytokines, and 
stained by a three-layer  (for polyclonal  antibodies) or four-layer  (for 
mAbs) peroxidase-antiperoxidase method as previously described 
(20, 21). Data quantitation and statistics were done as previously 
described (21). Evaluation of the slides was performed blindly. 
Results 
Intrath~/mic Injection of MBP  before Immunization  Protects 
against EAE.  We investigated whether intrathymic injec- 
tion of MBP before immunization protected animals against 
the development of clinical EAE. In these experiments, 1 mg 
of guinea pig MBP was injected intrathymically into Lewis 
rats 24 or 48 h before immunization with MBP/CFA. The 
animals received  no other treatment.  Control unmodified 
animals had an incidence of 5/5, a mean disease duration of 
3.8  _+  0.2 d, and a mean maximal score of 2.6  _+  0.4. The 
MBP-injected animals had an incidence of 1/6, a mean dis- 
ease duration of 0.5  _  0.5 and 0.33  _  0.33 d for 48 and 
24 h, respectively, and a mean maximal score of 0.33  _+ 0.33 
and 0.17  _+ 0.17 for 48 and 24 h, respectively (Fig. 1). These 
data indicate that intrathymic injection of MBP 24 or 48 h 
before immunization will protect against the development 
of clinical  EAE. 
To establish the uniqueness of the intrathymic approach, 
and to confirm that the tolerogenic effect of intrathymic in- 
jection of MBP was not due to systemic leakage of the an- 
tigen, animals were injected in the perithymic area with 1 
mg of MBP, and were immunized with MBP/CFA 48 h later. 
Perithymic injection of MBP was not protective against de- 
velopment of clinical EAE (mean duration --  5.6  _+ 0.6 and 
mean grade -- 3.0 _  0, p  =  NS, compared with OVA-injected 
animals), indicating that the tolerogenic effect observed with 
intrathymic injection is due to thymic recognition of the an- 
tigen, and not due to systemic leakage  of antigen into the 
periphery. 
We then investigated the time course of intrathymic MBP- 
induced hyporesponsiveness.  Intrathymic injection of 1 mg 
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Figure 1.  Disease  course in animals injected intrathymically with 1 mg 
MBP 24 and 48 h before immunization  compared with control immunized 
animals. Each data point represents the mean disease grade for five animals 
per group. 
of MBP was performed at various time intervals after immu- 
nization including days 1, 3, and 7,  and the clinical scores 
were compared with those animals that were intrathymicaUy 
injected with 1 mg MBP 48 h before immunization. In addi- 
tion,  to establish the specificity of the intrathymic tolero- 
genic effect, control animals were injected intrathymically with 
1 mg OVA. As seen in Table 1, the protective effect of in- 
trathymic injection of MBP is lost when performed after im- 
munization. These data indicate that thymic recognition of 
MBP has to occur before immunization if systemic tolerance 
is to be effected. 
Effect of Thymectomy.  To investigate the potential mecha- 
nisms mediating the tolerogenic effect of intrathymic injec- 
tion of MBP, we performed thymectomies at various time 
intervals after immunization. The animals were intrathymi- 
cally injected either with  1 mg MBP or 1 mg OVA 48 h 
before immunization with MBP/CFA.  As seen in Fig.  2, 
thymectomy done 1, 2, and 7 d after immunization abrogated 
the  tolerogenic  effect  of intrathymic  injection  of MBP. 
Thymectomy done on day 10 postimmunization, however, 
did not abrogate the tolerogenic effect, suggesting that the 
injected thymus is no longer required after 7 d postimmuni- 
zation. It is interesting to note that the onset of clinical dis- 
ease in this model is approximately day 10 postimmuniza- 
tion, and pathological changes can be seen 2-3 d before the 
onset of clinical disease (22).  Thymectomy did not prevent 
the induction of EAE in the control animals, although a slight 
decrease in severity and a delayed onset of disease were seen 
especially in animals thymectomized on day 10 postimmuni- 
zation. 
Proliferative Response of Draining Lymph Node Cells.  We 
then studied the proliferative responses of primed lympho- 
cytes from intrathymicaUy tolerized animals. Fig.  3  shows 
the proliferation of &aining lymph node cells from intrathymi- 
cally tolerized and control animals,  as measured by [3H]thy- 
midine incorporation. Lymphocytes from animals that were 
injected intrathymically with 1 mg of MBP 48 h before im- 
munization  with  MBP/CFA  exhibited  markedly reduced 
proliferation to MBP (relative response  --  0.2, p  --  0.001, 
n  --  3), but not to Mycobacterium tuberculosis (MT) (relative 
response =  2.6, n  =  3), as compared with lymphocytes from 
control rats injected with PBS. 
Intrathymic Injection of the Major Encephalitogenic Epitope of 
MBP Is Tolerogenic.  We compared the systemic tolerogenicity 
of intrathymic injection of the major encephalitogenic epi- 
tope of MBP  (peptide  [p]  71-90),  with  that  of a nonen- 
cephalitogenic epitope (p 21-40) (Fig. 4). Intrathymic injec- 
tion of 100/zg of p  71-90 48 h before immunization with 
Table  1.  Effect of Intrathymic Injection of MBP Pre- and Postimmunization 
Day of intrathymic  Thymic  Maximal 
injection*  injection  Incidence  Duration*  grade*  Disease index 
d 
-2  MBP  6/13  1.77  _+ 0.63 s  1.15  _+ 0.39s  0.94 
OVA  12/15  3.8  _+ 0.59  2.2  _+ 0.31  6.69 
+ 1  MBP  4/5  3.6  _+  1.0  2.4  _+ 0.6s  6.9 
OVA  5/5  5.6  _+ 0.24  4.0  _+ 0.0  22.4 
+3  MBP  5/5  4.2  _+ 0.86  2.6  _+ 0.4  10.9 
OVA  5/5  4.2  _+ 0.2  3.2  _+ 0.4  13.4 
+7  MBP  5/5  4.2  +  0.37  3.0  _+ 0.55  12.6 
OVA  5/5  4.8  _+ 0.2  3.2  _+ 0.2  15.4 
"Day of intrathymic injection is relative to the day of immunization with MBP/CFA. 
*Duration  and maximal grade  are expressed as mean +  SE. 
S0.0125 </, <0.025. 
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Figure  2.  Disease course in ani- 
mals intrathymically injected with 
1 mg MBP 48 h before immuniza- 
tion and thymectomized on days 1 
(a), 2 (b), 7 (c), and 10 (d) postim- 
raunization. Each data point repre- 
sents the mean disease grade of five 
animals per group. 
MBP/CFA was protective against development of clinical EAE 
(mean grade  =  1.2  +_  0.2,  mean  duration  =  1.8  +  0.6) 
indicating that thymic recognition of the immunodominant 
epitope ofMBP dowrtregulates the systemic immune response 
to MBP.  Intrathymic injection of 21-40  was not protective 
(mean  grade  =  3.0  _+  0,  mean  duration  =  4.6  _+  0.4). 
Intrathymic Injection of the Encephalitogenic  Epitope of MBP 
Suppresses CNS Inflammation.  Immunohistologic evaluation 
of brains from rats injected with the MBP encephalitogenic 
epitope showed almost complete absence of an inflammatory 
response,  which was in marked contrast to specimens from 
rats injected intrathymically with the nonencephalitogenic 
epitope (Table 2). Thus, sections from the latter group showed 
large perivascular and submeningeal infiltrates, consisting of 
T  cells and macrophages,  many of which were seen to be 
in contact with the ceU bodies of neurons (Fig. 5 a). About 
20-30%  of such cells  expressed  IL-2R  (Fig.  5  c) and were 
associated with expression of IL-2 (e), IFN-'), (g), and TNF-ol 
(i), whereas minimal or no cell infiltration (b) or cytokine 
expression  was  seen  in  sections  from  animals  receiving  in- 
4- 
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Figure  3.  Proliferative  response ofdralnlng lymph node (LN)  cells taken 
on day 9 postimmunization.  The results shown are from pooled LN of 
three animals per group. The two groups are represented on the x-axis 
as PBS and MBP for the animals receiving intrathymic injection of PBS 
and MBP, respectively. MBP and Mt antigens were used at 10/~g/ml. 
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Figure  4.  Disease course in animals injected intrathymically with the 
encephalitogenic MBP p 71-90 or the nonencephalitogenic p 21--40 and 
immunized 48 h later with MBP/CFA.  Each data point represents the 
mean disease grade of five animals per group. 
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Activation Markers, and Cytokines in Brains of Rats Immunized 
with MBP after Intrathyraic Injection of Encephalitogenic or 
Nonencephalitogenic MBP Peptide 
Nonencephalitogenic  Encephalitogenic 
(p 21-40)  (p 71-90) 
Leukocytes  96.2  _+  33.5  3.2  +  1.1" 
TCK c~/~/  58.4  _+ 26.1  0.9  +  0.8" 
Macrophages  33.7 +  18.7  3.7  _+ 2.1" 
IL-2R  18.6  _+ 7.3  0.0" 
Ia  78.3  _+ 25.3  1.5  _+ 0.9* 
ICAM-1  85.4 +  35.32  2.8  _+ 1.5" 
TNF-c~  2 +  + 
IL-1/3  2 +  0 
IL-2  2 +  0 
IL-4  1 +  0 
IL-6  1 +  0 
IL-8  2 +  _+ 
IFN-'),  2 +  0 
TGF-/~  _+  0 
PGE  _+  0 
Based on examination of 20 high-power fidds/rat and 3 rats/group. Num- 
bers indicate: mean labeled calls  _+  SD/100 nucleated cells in or adjacent 
to cerebral and cerebdlar small vessels. Cytokine data were graded semi- 
quantitatively as: (0) absence of labeling, ( _+ ) trace labeling, (1 + ) few 
small loci, and (2 +) multiple loci. 
*/, <0.001 compared with nonencephalitogenic peptide-injected group. 
trathymic injection of the encephalitogenic MBP peptide (d, 
f, h, and  j). Samples from the latter group also lacked expres- 
sion of IL-4, TGF-~, or PGE, each of which was previously 
associated with suppression of development of EAE in orally 
tolerized animals (21), and sections incubated with control 
antibodies were all unstained. 
Discussion 
We have shown that intrathymic injection of MBP induces 
systemic immune hyporesponsiveness as evidenced by pro- 
tection against actively induced EAE in vivo and decreased 
proliferative lymphocyte responses in vitro. The protective 
effect of intrathymic injection is not the result of systemic 
leakage of antigen, suggesting that MBP is processed  and 
presented by thymic APC. A recent report indicates  that a 
portion of an activated  T  cell population circulates  to the 
thymus, and may reside there for a prolonged period of time 
(10). Thus, peripheral T cells generated by immunization with 
MBP could potentially circulate through the thymus where 
they become inactivated. This hypothesis would explain abro- 
gation of the protective effect by thymectomy until day 10 
postimmunization, when pathological and clinical disease has 
already been initiated. Alternatively, regulatory thymocytes 
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could migrate to the periphery (23) to inactivate or suppress 
MBP-reactive  T  cells. 
There are two types of thymic APC, bone marrow-de- 
rived macrophages/dendritic cells and epithelial cells. Which 
cell type processes and presents MBP or MBP peptides is un- 
clear. There is evidence that each type of thymic APC has 
a different function in the induction of self-tolerance,  and 
in T  cell repertoire selection (8,  9). Positive selection may 
be mediated by thymic epithelial cells, and negative selection 
(clonal  anergy or deletion) may be mediated by the bone 
marrow-derived cells (7). T cells usually require two distinct 
signals for optimal stimulation: an antigen presented in the 
context of self-MHC,  and a costimulatory signal,  usually 
provided by APC (24). Thymic macrophages have been shown 
to have a selective antigen presentation defect to Thl clones 
that was attributed to lack of a costimulatory signal  (25). 
In addition, thymic epithelial cells have also been shown to 
induce in vivo tolerance to class I-incompatible skin grafts 
mediated by peripheral T  cell anergy (26,  27).  Studies  are 
in progress to investigate which thymic APC is responsible 
for MBP presentation in our model, and to better understand 
the exact mechanisms of acquired intrathymic tolerance. 
Protection from EAE is achieved by intrathymic injection 
of the encephalitogenic (p 71-90), but not by injecting the 
nonencephalitogenic (p 21-40), peptide of MBP. Immuno- 
histologic studies also showed that intrathymic injection of 
the encephalitogenic MBP peptide abrogated T cell and mac- 
rophage infiltration, and prevented upregnlation of Ia and 
ICAM-1 expression. These effects were associated with lack 
of T cell activation, as evidenced by complete absence of IL- 
2R, IL-2, or IFN-3' expression in the central nervous system, 
and provide in vivo morphologic correlates of the clinical and 
the in vitro proliferation data. 
Systemic tolerance has been induced in the EAE model by 
oral administration of MBP (28), or oral administration of 
either the encephalitogenic p 71-90 or the nonencephalito- 
genic p 21-40 (29). We have previously shown that oral toler- 
ance in EAE is associated with secretion of the suppressive 
cytokine TGF-~ in the target organ (21). This phenomenon 
is enhanced by oral administration of LPS, which results in 
IL-4 expression in the brain and is probably due to selective 
inhibition of Thl and stimulation of Th2 cells in vivo (21). 
Intrathymic injection of MBP or MBP peptides causes sup- 
pression of disease clinically and pathologically with evidence 
of downregnlation of activation and inflammatory cytokines 
in the target organ. However, in contrast to the oral toler- 
ance model, there is no upregulation of TGF-B and no evi- 
dence of immune deviation from Thl to Th2 cell function 
as evidenced by the absence of IL-4 expression.  Immuniza- 
tion with MBP/CFA leads to the generation of cells that are 
mainly reactive to p  71-90 (30).  This would suggest that 
thymic recognition of the immunodominant MBP epitope 
leads to clonal inactivation of the encephalitogenic cells via 
functional inactivation or anergy, or conversely, it may lead 
to peripheralization of regulatory cells that act on the afferent 
limb of the immune system, i.e., by active suppression of the 
encephalitogenic cells in the lymph nodes. 
Intrathymic injection of an autoantigen or its immuno- Figure  5.  Paired photomicrographs ofimmunoperoxidase staining ofcryostat sections of cerebri from rats on day 12 (peak of disease) after immuniza- 
tion with MBP/CFA.  (Le~) Rats injected  intrathymically with nonencephalitogenic MBP peptide;  (right)  rats receiving intrathymic injection of en- 
cephalitogenic  MBP peptide (hematoxylin counterstain;  x400). Intrathymic injection of eneephalitogenic  MBP peptide essentially abolished CNS inflam- 
mation, compared with injection of the control,  nonencephalitogenic peptide,  as shown by markedly decreased  perivascular  infiltrates  of:  (a and b) 
TCR c~/~ + cells, which, in the control group, were often (c and d) IL-2R  ~ (CD25), and associated with expression  of (e and f) II~2, (g and h) IFN-% 
and (i and j)  TNF-o~. 
564  Acquired  Thymic Tolerance  in Experimental Autoimmune Encephalomyelitis dominant peptide provides a novel approach for the study 
of the induction and regulation of T cell-mediated autoim- 
mune disease and an opportunity to define the contribution 
of the thymus in modulating T  cell-mediated immune re- 
sponses  in adult animals. 
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